Syndax Pharmaceuticals, Inc. cash flow to debt ratio of -93.22% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Syndax Pharmaceuticals, Inc.'s free cash flow has decreased 17.56% from $-274.90M last year to $-323.17M, signaling decreasing performance

Syndax Pharmaceuticals, Inc.'s debt to equity ratio is 39.03, which means that the company's assets are unhealthy financed, signaling financial risk.

Syndax Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 1.20 last year to 39.03 today, signaling weakened financials

Syndax Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Syndax Pharmaceuticals, Inc.'s interest coverage ratio is -2.27, which means that the company struggles to meet interest obligations, signaling financial risk.

Syndax Pharmaceuticals, Inc.'s profit margin has increased (-93.49%) in the last year from -1.35K% to -87.60%, signaling increasing performance

Syndax Pharmaceuticals, Inc.'s short-term assets of $528.08M exceed its short-term liabilities of $120.12M

Syndax Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Syndax Pharmaceuticals, Inc.'s return on equity of -372.94%, is lower than 15.00%, indicating bad performance

Syndax Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Syndax Pharmaceuticals, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Syndax Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Syndax Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Syndax Pharmaceuticals, Inc.'s yearly earnings has increased -10.46% since last year from $-318.76M to $-285.42M, signaling increasing performance

Syndax Pharmaceuticals, Inc.'s yearly revenue has increased 627.84% since last year from $23.68M to $172.35M, signaling increasing performance

ROIC -32.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Syndax Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Syndax Pharmaceuticals, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Syndax Pharmaceuticals, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Syndax Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Syndax Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Syndax Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Syndax Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Syndax Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Syndax Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Syndax Pharmaceuticals, Inc. has a price-to-book ratio of 120.04x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Syndax Pharmaceuticals, Inc. has a price-to-sales ratio of 7.19x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue